Core Insights - Teva Pharmaceutical Industries Limited's shares have increased by 21.6% over the past three months due to successful launches of biosimilars and high-value generics, strong sales growth of newer branded drugs, and cost-cutting measures [1] Branded Drug Growth - Teva is experiencing market share growth for its newest branded drugs, Austedo and Ajovy, with expectations for continued sales growth from patient expansion and international launches [3] - The company anticipates annual revenues exceeding $2.5 billion from Austedo by 2027, bolstered by the launch of Austedo XR [4] - Uzedy, launched in May 2023, is projected to generate approximately $160 million in sales by 2025 [5] - Teva's branded pipeline includes olanzapine and duvakitug, with plans for phase III trials and new drug applications in the coming years [6][7] Generics and Biosimilars Pipeline - Teva has launched several biosimilars and complex generics, including products from major pharmaceutical companies [8] - The company has a strong pipeline of biosimilars, with plans to launch seven in the U.S. and four in Europe between 2025 and 2027 [10] - Teva's U.S. generics and biosimilars business grew by 15% in 2024, driven by new product launches [11] Financial Performance and Valuation - Teva's stock has underperformed the industry, losing 25% year-to-date compared to a 9.5% decline in the industry [13][14] - The stock is trading at a price/earnings ratio of 6.30, lower than the industry average of 10.17, but above its 5-year mean of 4.11 [15] - The Zacks Consensus Estimate for earnings has seen a slight decline for 2025 but an increase for 2026 [19] Long-term Growth Prospects - Teva's newer drugs and stable generics business are contributing to a revival in top-line growth [21] - The company is optimizing operations for efficiency, aiming for an adjusted operating margin of 30% by 2027 [22] - Recent credit outlook upgrades from Fitch, Moody's, and S&P reflect improved growth prospects for Teva [23]

PIVOT TO GROWTH Accelerate Growth May 29, 2025 Teva Pharmaceutical Industries Ltd. Welcome! and other factors discussed in our Quarterly Report on Form 10-Q for the first quarter of 2025 and in our Annual Report on Form 10-K for the year ended December 31, 2024, including in the sections captioned "Risk Factors" and "Forward-looking Statements." Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other ...

Teva outlines acceleration path into a leading biopharma companyInnovative medicines franchise on track to exceed $5 billion by 2030, led by AUSTEDO® (deutetrabenazine), AJOVY® (fremanezumab), UZEDY® (risperidone) and late-stage pipeline with blockbuster potentialReaffirming 2027 financial targets, including 30% operating profit margin, driven by innovative growth and transformation programs TEL AVIV, Israel and PARSIPPANY, N.J., May 29, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and ...

Core Viewpoint - Teva Pharmaceutical Industries Limited's stock has experienced a 12.9% increase over the past month, primarily following the announcement of its first-quarter 2025 results, which were mixed in nature [1][2]. Financial Performance - Teva's first-quarter results showed earnings that exceeded estimates but sales that fell short. The company slightly adjusted its sales guidance for 2025, lowering the upper end while increasing the lower end of its EPS range [2]. - The company anticipates U.S. tariffs to have an "immaterial impact" on profits, which are already included in its 2025 earnings outlook [3]. - Teva expects to achieve approximately $700 million in net cost savings by 2027, driven by operational efficiencies and growth in branded drugs [4]. Product Pipeline and Growth - Teva is experiencing growth in its branded drugs, particularly Austedo and Ajovy, with Ajovy sales increasing by 18% in 2024 and 26% in Q1 2025. Austedo is projected to generate over $2.5 billion in annual revenues by 2027 [6][7]. - The company launched Uzedy in May 2023, achieving sales of approximately $117 million in 2024, exceeding its target [8]. - Teva's pipeline includes promising products like olanzapine and duvakitug, with plans for a phase III program on duvakitug in late 2025 [9]. Generics and Biosimilars - Teva has successfully launched several high-value complex generics and biosimilars, contributing to a 15% growth in its U.S. generics/biosimilars business in 2024 [10][13]. - The company plans to launch seven biosimilars in the U.S. and four in Europe between 2025 and 2027, with several under review [12]. Legal and Settlement Developments - Teva has resolved its nationwide opioid litigation, agreeing to pay up to $4.25 billion over 13 years, which includes delivering its generic version of Narcan [15]. - The settlement has allowed the company to clear a significant legal hurdle, potentially stabilizing its financial outlook [25]. Valuation and Market Position - Teva's stock is currently trading at a price/earnings ratio of 6.51, which is lower than the industry average of 9.70, indicating an attractive valuation [19]. - Despite a 23% decline in stock value year-to-date, the company is positioned for potential long-term growth due to its new product launches and stable generics business [16][24].

21世纪经济报道记者韩利明上海报道 日前，全球仿制药巨头梯瓦（Teva）在2025年第一季度财报电话会议中，披露了向领先生物制药公司转 型的规划，目标是在对业务增长及产品管线再投资后，到2027年实现约7亿美元净节省，同时抵消来那 度胺（瑞复美、Revlimid）仿制药的利润损失，实现30%营业利润率。 同时，梯瓦也在加快推进某些关键管线资产的开发，包括在炎症性肠病治疗领域，抗TL1A 药物 duvakitug于克罗恩病和溃疡性结肠炎的 2b 期临床试验中取得积极结果；奥氮平LAI 计划于2025年提交 新药申请（NDA）；DARI双效哮喘急救吸入器预计2025年完成Ⅲ期临床试验入组，2026年有望迎来Ⅲ 期关键数据读出。 从区域市场表现来看，美国市场依然是梯瓦的业绩核心。2025年第一季度，其美国部门收入19.1亿美 元，同比增长10.72%，占总营收的48.97%；利润达5.32亿美元，同比增幅高达52%，毛利率从49.8%提 升至55.4%。 其中包括三项举措，一是借助业务中心、人工智能与数字化手段，减少层级，提升灵活性、速度与精准 度，使一般及行政费用占比降低 100 个基点；二是精减人员，计划裁员约 ...

Core Viewpoint - Teva Pharmaceutical Industries reported mixed first-quarter 2025 results, beating earnings estimates but missing revenue expectations, with adjusted earnings of 52 cents per share and revenues of $3.89 billion [1][16]. Financial Performance - Adjusted earnings increased by 8% year over year, driven by higher operating profits [1]. - Total revenues rose 2% year over year on a reported basis and 5% on a constant currency basis [1]. - U.S. segment sales reached $1.91 billion, an 11% increase year over year, surpassing estimates [2]. Product Performance - Revenues from generic products in the U.S. rose 5% to $849 million, primarily due to the launch of Simlandi, a generic version of Humira [3][4]. - Sales of Austedo, a Huntington's disease drug, increased by 40% year over year to $396 million, exceeding estimates [6]. - Ajovy sales grew 18% year over year to $53 million, while Uzedy generated $39 million in sales [7]. Regional Performance - Europe segment revenues declined 6% year over year to $1.19 billion, missing estimates [9][10]. - International Markets segment sales decreased 2% year over year to $582 million, also missing estimates [11]. Guidance and Future Outlook - Teva expects total revenues for 2025 to be between $16.8 billion and $17.2 billion, slightly lowering the upper end of the previous guidance [13]. - Adjusted EPS guidance for 2025 was raised to a range of $2.45-$2.65 per share [13]. - The company anticipates $700 million in cost savings by 2027, with an adjusted operating margin target of 30% [15]. Market Reaction - Following the earnings release, Teva's stock rose over 9%, despite a year-to-date decline of 20.1% compared to the industry decline of 17.6% [19].

Core Viewpoint - Teva Pharmaceutical Industries Ltd reported its Q1 2025 financial results, showing a revenue increase but missing analyst expectations, while also providing an optimistic outlook for future earnings and operational efficiency [1][3][4]. Financial Performance - Teva's revenue for Q1 2025 was $3.89 billion, a 5% increase year-over-year, but below the analyst estimate of $4.00 billion [1]. - Adjusted earnings per share were 52 cents, surpassing estimates of 48 cents [3]. - Gross profit margin improved to 48.2% from 46.4% year-over-year, with adjusted gross profit margin rising to 52.8% from 51.4% [3]. Product Performance - Austedo's worldwide revenues reached $411 million in Q1 2025, marking a 39% increase in local currency compared to Q1 2024, with U.S. revenues growing by 40% to $396 million [1]. - Ajovy's global revenues were $139 million, a 26% increase in local currency terms compared to Q1 2024 [2]. - Uzedy's global revenues were $39 million in Q1 2025 [6]. Guidance and Outlook - Teva raised its fiscal 2025 adjusted earnings per share guidance from $2.35-$2.65 to $2.45-$2.65, aligning closely with the consensus of $2.55 [3][4]. - The company narrowed its 2025 sales guidance from $16.8 billion-$17.4 billion to $16.8 billion-$17.2 billion, compared to the consensus of $17.24 billion [4]. - Teva increased its Austedo 2025 sales outlook from approximately $1.9-2.05 billion to $1.95-2.05 billion [4]. Operational Strategy - Teva's CEO highlighted the company's transition into the "Acceleration Phase" of its Pivot to Growth Strategy, aiming for a 30% operating margin and $700 million in net savings by 2027 [3]. - The generics business showed growth across all regions, with a 5% increase in the U.S., 1% in Europe, and 2% in International Markets, all in local currency terms compared to Q1 2024 [6].

May 7, 2025 Teva Pharmaceutical Industries Ltd. This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management's current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. These forward-looking statements ...

For an accessible version of this Press Release, please visit www.tevapharm.com Q1 2025 Highlights: (1) Revised 2025 outlook now includes no contribution from the Japan BV after Q1 and continues to include a full year contribution from Teva API, as well as exclude the expected income from development milestone payments from Sanofi in connection with the Phase 3 ulcerative colitis and Crohn's Disease initiations for duvakitug. (2) This outlook is based on the existing tariff and trade environment as of May 7 ...